360 related articles for article (PubMed ID: 12368671)
1. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience.
Jain A; Nalesnik M; Reyes J; Pokharna R; Mazariegos G; Green M; Eghtesad B; Marsh W; Cacciarelli T; Fontes P; Abu-Elmagd K; Sindhi R; Demetris J; Fung J
Ann Surg; 2002 Oct; 236(4):429-36; discussion 436-7. PubMed ID: 12368671
[TBL] [Abstract][Full Text] [Related]
2. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
[TBL] [Abstract][Full Text] [Related]
3. A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy.
Barış Z; Özçay F; Yılmaz Özbek Ö; Haberal N; Sarıalioğlu F; Haberal M
Turk J Gastroenterol; 2018 May; 29(3):354-360. PubMed ID: 29755021
[TBL] [Abstract][Full Text] [Related]
4. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
Newell KA; Alonso EM; Kelly SM; Rubin CM; Thistlethwaite JR; Whitington PF
J Pediatr; 1997 Jul; 131(1 Pt 1):98-104. PubMed ID: 9255199
[TBL] [Abstract][Full Text] [Related]
5. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
6. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
[TBL] [Abstract][Full Text] [Related]
7. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
[TBL] [Abstract][Full Text] [Related]
8. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
Cacciarelli TV; Green M; Jaffe R; Mazariegos GV; Jain A; Fung JJ; Reyes J
Transplantation; 1998 Oct; 66(8):1047-52. PubMed ID: 9808490
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation.
Chiou FK; Beath SV; Morland B; Hartley J; van Mourik I; Abdel-Hady M; Kelly DA; Sharif K; Gupte GL
Transplantation; 2020 Jul; 104(7):1429-1436. PubMed ID: 31651718
[TBL] [Abstract][Full Text] [Related]
10. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
11. Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level.
Eshraghian A; Imanieh MH; Dehghani SM; Nikeghbalian S; Shamsaeefar A; Barshans F; Kazemi K; Geramizadeh B; Malek-Hosseini SA
World J Gastroenterol; 2017 Feb; 23(7):1224-1232. PubMed ID: 28275302
[TBL] [Abstract][Full Text] [Related]
12. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation.
Cao S; Cox K; Esquivel CO; Berquist W; Concepcion W; Ojogho O; Monge H; Krams S; Martinez O; So S
Transplantation; 1998 Oct; 66(7):851-6. PubMed ID: 9798693
[TBL] [Abstract][Full Text] [Related]
13. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.
Kasiske BL; Kukla A; Thomas D; Wood Ives J; Snyder JJ; Qiu Y; Peng Y; Dharnidharka VR; Israni AK
Am J Kidney Dis; 2011 Dec; 58(6):971-80. PubMed ID: 21930332
[TBL] [Abstract][Full Text] [Related]
14. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
Shapiro R; Nalesnik M; McCauley J; Fedorek S; Jordan ML; Scantlebury VP; Jain A; Vivas C; Ellis D; Lombardozzi-Lane S; Randhawa P; Johnston J; Hakala TR; Simmons RL; Fung JJ; Starzl TE
Transplantation; 1999 Dec; 68(12):1851-4. PubMed ID: 10628763
[TBL] [Abstract][Full Text] [Related]
15. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
[TBL] [Abstract][Full Text] [Related]
16. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
Liu M; Husain S; Famure O; Li Y; Kim SJ
Prog Transplant; 2019 Jun; 29(2):185-193. PubMed ID: 30845885
[TBL] [Abstract][Full Text] [Related]
17. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study.
Lo RC; Chan SC; Chan KL; Chiang AK; Lo CM; Ng IO
J Clin Pathol; 2013 May; 66(5):392-8. PubMed ID: 23423516
[TBL] [Abstract][Full Text] [Related]
19. Primary sclerosing cholangitis and other risk factors for post-transplant lymphoproliferative disease after liver transplantation in adults.
Ruijter BN; Tushuizen ME; van der Helm D; Hew M; Reeven M; Vossen ACTM; Metselaar HJ; Alwayn IPJ; Dubbeld J; Polak WG; van Hoek B
Liver Transpl; 2024 Jun; 30(6):640-646. PubMed ID: 37698933
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
